CompareMarketResearchRequest a sample
Home / Healthcare / Cell Therapy

Healthcare · Market report

Cell Therapy Market Size, Share and Forecast 2026-2036

The global cell therapy market is worth USD 9.4 bn in 2026 and is forecast to reach USD 58.0 bn by 2036, growing at a 20.0% CAGR. United States is the largest country market and CAR-T cells is the largest by cell type segment.

USD 9.4 bnMarket size 2026
USD 58.0 bnForecast 2036
20.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global cell therapy market is worth USD 9.4 bn in 2026 and is forecast to reach USD 58.0 bn by 2036, growing at a 20.0% CAGR. United States is the largest country market and CAR-T cells is the largest by cell type segment.

ScopeCommercial cell therapies in which living cells are given to patients, including CAR-T therapies, tumour-infiltrating lymphocytes, mesenchymal stem cell products and cord blood-based treatments.
IndustryHealthcare
Value 2025USD 7.5 bn
Value 2026USD 9.4 bn
Value 2036USD 58.0 bn
CAGR 2026-203620.0%
Volume 202627.9 thousand patients
Volume 2036201 thousand patients
Average price 2026USD 335,800 per patient
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Cell Therapy market size and forecast, 2026-2036

Exhibit 1The global cell therapy market is forecast to grow from USD 9.4 bn in 2026 to USD 58.0 bn by 2036, more than five times its 2026 sizeGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 20.0%
Cell Therapy market value, 2025 to 2036Market value by year. 2025: USD 7.5 bn; 2026: USD 9.4 bn; 2027: USD 11.2 bn; 2028: USD 13.5 bn; 2029: USD 16.2 bn; 2030: USD 19.4 bn; 2031: USD 23.3 bn; 2032: USD 28.0 bn; 2033: USD 33.6 bn; 2034: USD 40.3 bn; 2035: USD 48.4 bn; 2036: USD 58.0 bn. Compound annual growth rate 2026 to 2036: 20.0%.20259.4 bn202623.3 bn203158.0 bn203620.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 9.4 bn
2027USD 11.2 bn
2028USD 13.5 bn
2029USD 16.2 bn
2030USD 19.4 bn
2031USD 23.3 bn
2032USD 28.0 bn
2033USD 33.6 bn
2034USD 40.3 bn
2035USD 48.4 bn
2036USD 58.0 bn

Cell Therapy market segmentation

By cell type

Exhibit 2CAR-T cells is the largest segment by cell type, with 72.0% of 2026 revenueEstimated share of 2026 global revenue, by cell type
Cell Therapy market share by cell type, 2026Share of 2026 revenue by cell type. CAR-T cells: 72.0%; Stem cell therapies: 15.0%; Other immune cells: 8.0%; Others: 5.0%.CAR-T cells72.0%Stem cell therapies15.0%Other immune cells8.0%Others5.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
CAR-T cells72.0%72.1%USD 6.8 bn20.0%
Other immune cells8.0%12.0%USD 750 mn25.0%
Stem cell therapies15.0%11.7%USD 1.4 bn17.0%
Others5.0%4.2%USD 469 mn18.0%

By indication

Exhibit 3Blood cancers adds the most revenue by indication, growing from USD 7.1 bn in 2026 to USD 33.8 bn by 2036Estimated revenue in USD by indication, 2026 and 2036 forecast
Cell Therapy market by indication, 2026 and 2036Revenue by indication in 2026 and 2036. Blood cancers: USD 7.1 bn in 2026, USD 33.8 bn in 2036, change +375%; Solid tumours: USD 562 mn in 2026, USD 16.1 bn in 2036, change +2,757%; Other: USD 1.4 bn in 2026, USD 4.3 bn in 2036, change +207%; Autoimmune: USD 281 mn in 2026, USD 3.8 bn in 2036, change +1,262%.20262036 forecastChangeBlood cancers+375%7.1 bn33.8 bnSolid tumours+2,757%562 mn16.1 bnOther+207%1.4 bn4.3 bnAutoimmune+1,262%281 mn3.8 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Blood cancers76.0%58.3%USD 7.1 bn16.9%
Solid tumours6.0%27.7%USD 562 mn39.8%
Autoimmune3.0%6.6%USD 281 mn29.8%
Other15.0%7.4%USD 1.4 bn11.9%

By therapy type

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Autologous56.0%52.0%USD 5.2 bn19.1%
Allogeneic34.0%36.0%USD 3.2 bn20.7%
Off-the-shelf iPSC derived10.0%12.0%USD 938 mn22.2%

By phase of care

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Preclinical and early clinical14.0%12.0%USD 1.3 bn18.2%
Late clinical22.0%18.0%USD 2.1 bn17.6%
Commercial supply64.0%70.0%USD 6.0 bn21.1%

By product source

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
CAR-T50.0%48.0%USD 4.7 bn19.5%
Stem cell therapy24.0%22.0%USD 2.2 bn19.0%
TCR and TIL10.0%12.0%USD 938 mn22.2%
NK and others16.0%18.0%USD 1.5 bn21.4%

Top 25 countries for cell therapy by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 97.0% of 2026 revenue and the 25 countries below together hold 99.3%.

Exhibit 4United States is the largest country market at USD 5.6 bn in 2026, and the three largest countries hold 72.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Cell Therapy market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 5.6 bn, 60.0%; Germany: USD 562 mn, 6.0%; China: USD 562 mn, 6.0%; France: USD 469 mn, 5.0%; Japan: USD 469 mn, 5.0%; United Kingdom: USD 375 mn, 4.0%; Italy: USD 375 mn, 4.0%; Spain: USD 281 mn, 3.0%; Canada: USD 188 mn, 2.0%; Netherlands: USD 188 mn, 2.0%.United States5.6 bn 60.0%Germany562 mn 6.0%China562 mn 6.0%France469 mn 5.0%Japan469 mn 5.0%United Kingdom375 mn 4.0%Italy375 mn 4.0%Spain281 mn 3.0%Canada188 mn 2.0%Netherlands188 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 5.6 bn60.0%USD 34.4 bn19.9%
2GermanyUSD 562 mn6.0%USD 3.2 bn19.0%
3ChinaUSD 562 mn6.0%USD 5.6 bn25.9%
4FranceUSD 469 mn5.0%USD 2.6 bn18.7%
5JapanUSD 469 mn5.0%USD 2.8 bn19.8%
6United KingdomUSD 375 mn4.0%USD 2.1 bn18.7%
7ItalyUSD 375 mn4.0%USD 1.9 bn17.7%
8SpainUSD 281 mn3.0%USD 1.5 bn17.8%
9CanadaUSD 188 mn2.0%USD 1.0 bn18.7%
10NetherlandsUSD 188 mn2.0%USD 1.0 bn18.7%
11SwitzerlandUSD 43 mn0.5%USD 261 mn19.7%
12IsraelUSD 33 mn0.3%USD 197 mn19.6%
13AustraliaUSD 25 mn0.3%USD 151 mn19.6%
14South KoreaUSD 24 mn0.3%USD 168 mn21.3%
15BelgiumUSD 19 mn0.2%USD 116 mn20.0%
16SwedenUSD 14 mn0.1%USD 87 mn20.0%
17AustriaUSD 12 mn0.1%USD 70 mn19.0%
18BrazilUSD 9.4 mn0.1%USD 70 mn22.2%
19IndiaUSD 9.4 mn0.1%USD 64 mn21.1%
20SingaporeUSD 7.5 mn0.08%USD 52 mn21.4%
21PolandUSD 6.6 mn0.07%USD 46 mn21.6%
22DenmarkUSD 5.6 mn0.06%USD 35 mn20.0%
23TaiwanUSD 4.7 mn0.05%USD 29 mn20.0%
24Saudi ArabiaUSD 2.8 mn0.03%USD 23 mn23.5%
25IrelandUSD 2.8 mn0.03%USD 17 mn20.0%
Rest of worldUSD 62 mn0.7%USD 412 mn20.9%
Exhibit 5United States and China account for 70% of the USD 48.7 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Cell Therapy market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 9.4 bn. United States: +USD 28.8 bn; China: +USD 5.1 bn; Germany: +USD 2.6 bn; Japan: +USD 2.4 bn; France: +USD 2.1 bn; 20 other countries: +USD 7.3 bn; Rest of world: +USD 350 mn. Market value 2036: USD 58.0 bn.Market value 20269.4 bnUnited States+28.8 bnChina+5.1 bnGermany+2.6 bnJapan+2.4 bnFrance+2.1 bn20 other countries+7.3 bnRest of world+350 mnMarket value 203658.0 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Gilead Sciences (Kite)
  • Bristol Myers Squibb
  • Novartis
  • Johnson and Johnson
  • Legend Biotech

Group 2: Regional and specialist players

  • Iovance Biotherapeutics
  • Vertex Pharmaceuticals
  • Mesoblast
  • Vericel
  • Atara Biotherapeutics
  • Adaptimmune
  • JCR Pharmaceuticals

Group 3: Emerging and niche players

  • JW Therapeutics
  • CARsgen Therapeutics
  • Autolus Therapeutics
  • IASO Bio
  • Juventas Cell Therapy
  • Medipost
  • Pharmicell

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the cell therapy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 20.0% is calculated from the resulting values.

The market is divided by cell type, by indication, by therapy type, by phase of care, by product source. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the cell therapy market?

The global cell therapy market is estimated at USD 7.5 bn in 2025 and USD 9.4 bn in 2026.

How fast will the cell therapy market grow?

It is forecast to reach USD 58.0 bn by 2036, a compound annual growth rate of 20.0% from 2026, an increase of USD 48.7 bn.

Which country is the largest market for cell therapy?

United States is the largest market by revenue at USD 5.6 bn in 2026, 60.0% of the global total. The three largest countries together hold 72.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 25.9% a year from 2026 to 2036.

Which cell therapy segment is largest?

In the by cell type split, CAR-T cells is the largest segment with 72.0% of 2026 revenue.

Who are the leading cell therapy companies?

Global leaders include Gilead Sciences (Kite), Bristol Myers Squibb, Novartis, Johnson and Johnson.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Cell Culture Media Cell-Free DNA Testing Transplant →

All Healthcare markets →

Request a sample